STAT3 and Miyoshi myopathy: Although earlier in vitro studies indicated a potential usefulness of TZD for the treatment of MM through mechanisms of suppressing angiogenesis [34], inactivating STAT3 [35], inhibiting the adhesive interactions of MM cells with bone marrow stromal cells [36] and acting as a mitochondrial inhibitor [38] and as an activator of AMPK [39,40], our study did not fully support a significant overall benefit in humans (Table 2).